A fortified nutritional composition for elderly frail / sarcopenic individuals, its preparation method, and its application.

By using the synergistic ratio of calcium β-hydroxy-β-methylbutyrate, L-leucine, and vitamin D3, along with cyclodextrin inclusion technology and food-grade excipients, a fortified nutritional composition specifically for elderly frailty/sarcopenia was prepared. This solved the problem of single-component products in existing products, achieved closed-loop regulation of muscle protein synthesis and degradation, improved product stability, and improved muscle degeneration symptoms and medication adherence in the elderly.

CN123100834APending Publication Date: 2026-11-17BEIJING SHIJITAN HOSPITAL CAPITAL MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611486385.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-23
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing nutritional intervention products for sarcopenia have problems such as single component action, no synergistic effect, poor suitability for the elderly, low stability, and limited intervention effect. They are also prone to causing gastrointestinal adverse reactions and are not designed for the gastrointestinal tolerance and metabolic characteristics of the elderly, resulting in poor adherence to use.

Method used

By employing a synergistic ratio of calcium β-hydroxy-β-methylbutyrate, L-leucine, and vitamin D3, combined with food-grade excipients such as whey protein isolate, soybean oligopeptides, fructooligosaccharides, and inulin, and through cyclodextrin inclusion technology and graded mixing process, a fortified nutritional composition specifically for elderly frailty/sarcopenia has been prepared, which improves intestinal absorption and product stability.

Benefits of technology

It achieves closed-loop regulation of skeletal muscle protein synthesis and degradation, significantly improves muscle protein synthesis capacity, alleviates muscle atrophy symptoms in the elderly, and at the same time improves product stability and intestinal absorption rate, reduces gastrointestinal adverse reactions, and enhances patient compliance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

This invention relates to the field of functional food technology. It provides a fortified nutritional composition for elderly individuals with frailty / sarcopenia, using a defined ratio of calcium β-hydroxy-β-methylbutyrate, L-leucine, and vitamin D3 as core active components. This is combined with small-molecule active peptides, prebiotics, minerals, and food-grade excipients to construct a synergistic nutritional system, forming a synergistic mechanism of "promoting synthesis, inhibiting decomposition, enhancing function, and improving absorption." This precisely matches the metabolic characteristics of elderly individuals with frailty / sarcopenia, improving muscle mass, strength, and motor ability, and has a wide range of applications. Furthermore, this invention optimizes the component ratio, avoiding gastrointestinal irritation caused by high doses of amino acids, resulting in a product with high safety, strong stability, and good elderly compliance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of functional food technology, and in particular to a fortified nutritional composition for elderly frail / sarcopenic individuals, its preparation method, and its application. Background Technology

[0002] Sarcopenia is a geriatric syndrome characterized by progressive loss of skeletal muscle mass, decreased muscle strength, and decline in physical motor function with age. It often occurs comorbid with frailty. Patients with frailty and sarcopenia mainly exhibit decreased body weight, physical fatigue, slowed walking speed, decreased grip strength, and declining mobility, significantly increasing the risk of falls, fractures, disability, recurrent hospitalizations, and all-cause mortality in the elderly. It is a core condition affecting the health and quality of life of the elderly.

[0003] Anabolic resistance is common among the elderly, with skeletal muscle exhibiting a significantly reduced ability to respond to amino acid synthesis signals, and the rate of muscle protein breakdown far exceeding the rate of synthesis. At the same time, the elderly suffer from reduced gastrointestinal digestion and absorption, insufficient daily intake of high-quality protein, lack of outdoor sunlight, and chronic low-grade inflammation, making it impossible for conventional dietary supplements to reverse the process of muscle loss.

[0004] Existing nutritional intervention products for sarcopenia have significant technical deficiencies: Leucine supplementation alone only weakly activates muscle protein synthesis pathways without inhibiting degradation; β-hydroxy-β-methylbutyric acid (HMB) supplementation alone only inhibits muscle protein degradation, with insufficient synthetic driving capacity; and vitamin D supplementation alone only regulates calcium and phosphorus metabolism and muscle nerve function, but cannot directly regulate muscle protein metabolism. The intervention effects of these three components alone are limited, and binary combinations suffer from imbalances, metabolic competition, and low bioavailability. Furthermore, existing products are mostly designed for fitness enthusiasts and have not been optimized for the gastrointestinal tolerance and metabolic characteristics of elderly and frail individuals, easily causing gastrointestinal adverse reactions such as bloating, acid reflux, and diarrhea, resulting in poor long-term adherence among the elderly. In addition, existing formulations suffer from poor stability, easy oxidation and inactivation of active ingredients, and easy stratification and clumping of powders, leading to poor industrial adaptability.

[0005] To address the shortcomings of existing technologies, such as single component action, lack of synergistic effect, poor suitability for the elderly, low stability, and limited intervention effect, this invention develops a fortified nutritional composition specifically for elderly frailty / sarcopenia that features precise formulation, synergistic effect, and high safety. Summary of the Invention

[0006] The purpose of this invention is to provide a fortified nutritional composition for elderly people with frailty / sarcopenia, in which the components can work synergistically to better assist in regulating the symptoms of sarcopenia and frailty in the elderly.

[0007] To achieve the above-mentioned objectives, the present invention provides the following technical solution:

[0008] This invention provides a fortified nutritional composition for elderly frail / sarcopenic individuals, comprising the following core active ingredients in parts by weight: 1-3 parts of calcium β-hydroxy-β-methylbutyrate, 0.8-2 parts of L-leucine, and 0.0000125-0.00005 parts of vitamin D3.

[0009] Preferably, the product also includes food-grade excipients, which, by weight, include: 8-15 parts whey protein isolate, 2-5 parts soybean oligopeptides, 1-2.5 parts fructooligosaccharides, 0.5-1.5 parts inulin, 0.3-0.6 parts calcium citrate, 0.005-0.015 parts zinc lactate, 0.02-0.05 parts magnesium sulfate, 0.05-0.15 parts vitamin C, 3-8 parts erythritol, 0.1-0.3 parts fumed silica, and 0.05-0.2 parts magnesium stearate.

[0010] Preferably, the dosage form of the composition is any one of powder, granules, chewable tablets, or oral suspension.

[0011] The present invention also provides a method for preparing the fortified nutritional composition, comprising the following steps:

[0012] (1) Mix fumed silica with pretreated vitamin D3 to obtain mixture A;

[0013] (2) Mix mixture A with calcium β-hydroxy-β-methylbutyrate and L-leucine to obtain mixture B;

[0014] (3) Add whey protein isolate, soybean oligopeptides, fructooligosaccharides, inulin, calcium citrate, zinc lactate, magnesium sulfate, vitamin C and erythritol into mixture B in three equal portions, and then add magnesium stearate and mix well to obtain the final product.

[0015] Preferably, the pretreatment in step (1) is performed by dissolving vitamin D3 in medium-chain triglycerides, then adding β-cyclodextrin for inclusion reaction, and freeze-drying.

[0016] Preferably, the mass ratio of vitamin D3 to β-cyclodextrin is 1:(250-1000).

[0017] Preferably, the inclusion reaction is carried out at a temperature of 25±1℃ and for a time of 50-70 min.

[0018] Preferably, in step (3), during the process of adding the same amount of magnesium stearate three times, the mixing time after each addition is 5-10 minutes; the mixing time of magnesium stearate is 3-8 minutes.

[0019] The application of the fortified nutritional composition described in this invention in the preparation of functional foods that help treat frailty / sarcopenia in the elderly.

[0020] By adopting the above technical solution, the present invention has the following beneficial effects:

[0021] This invention clarifies the synergistic ratio range of calcium β-hydroxy-β-methylbutyrate, leucine, and vitamin D3. L-leucine specifically activates the mTORC1 synthesis pathway, overcoming anabolism resistance in the elderly and initiating de novo synthesis of skeletal muscle proteins. Calcium β-hydroxy-β-methylbutyrate inhibits the ubiquitin-proteasome degradation pathway in skeletal muscle, reducing muscle protein loss and repairing damaged muscle fibers. Vitamin D3 optimizes neuromuscular junction transmission function in skeletal muscle, enhancing muscle contraction ability, while upregulating intestinal nutrient transport proteins, significantly improving the intestinal absorption and utilization rate of L-leucine and HMB-Ca. The synergistic effect of these three components constructs a closed-loop mechanism for muscle protein synthesis, degradation, neural function regulation, and nutrient absorption, effectively solving the problem of anabolism resistance in the elderly and significantly improving the auxiliary conditioning effect. Furthermore, the addition of small molecule peptides, prebiotics, minerals, and antioxidant excipients further enhances nutrient absorption and product stability.

[0022] This invention uses cyclodextrin inclusion technology to solve the problem of oxidative inactivation of fat-soluble vitamins, and the graded mixing process eliminates the problems of powder stratification and uneven distribution of active ingredients, resulting in good batch stability and long shelf life of the product. Detailed Implementation

[0023] This invention provides a fortified nutritional composition for elderly frail / sarcopenic individuals, comprising the following core active ingredients: calcium β-hydroxy-β-methylbutyrate, L-leucine, and vitamin D3.

[0024] In this invention, L-leucine specifically activates the mTORC1 synthesis pathway, overcoming aging-related anabolic resistance and initiating de novo synthesis of skeletal muscle proteins; β-hydroxy-β-methylbutyrate calcium inhibits the skeletal muscle ubiquitin-proteasome degradation pathway, reducing muscle protein loss and repairing damaged muscle fibers; vitamin D3 optimizes the neuromuscular junction transmission function of skeletal muscle, enhances muscle contraction ability, and simultaneously upregulates intestinal nutrient transport proteins, significantly improving the intestinal absorption and utilization rate of L-leucine and HMB-Ca. The three work synergistically to form a closed-loop regulatory system of synthesis-degradation-function-absorption, which can better assist in the treatment of frail elderly / sarcopenia patients.

[0025] In this invention, the calcium β-hydroxy-β-methylbutyrate is preferably 1-3 parts by weight, more preferably 1.2-2.5 parts, and even more preferably 1.5 parts by weight; the L-leucine is preferably 0.8-2 parts by weight, more preferably 1-1.6 parts, and even more preferably 1.2 parts by weight; and the vitamin D3 is preferably 0.0000125-0.00005 parts by weight, more preferably 0.000015-0.00004 parts, and even more preferably 0.000025 parts by weight.

[0026] The present invention also includes food-grade excipients, which include: whey protein isolate, soybean oligopeptides, fructooligosaccharides, inulin, calcium citrate, zinc lactate, magnesium sulfate, vitamin C, erythritol, fumed silica, and magnesium stearate.

[0027] In this invention, whey protein isolate and soybean oligopeptides, as high-quality proteins and small-molecule peptides, provide a basic nitrogen source for skeletal muscle synthesis. The small-molecule peptides are suitable for the weak digestive and absorption systems of the elderly, strengthening the nutritional foundation of muscles. Fructooligosaccharides and inulin, as prebiotics, can regulate intestinal flora and improve the absorption and utilization of core active components (calcium β-hydroxy-β-methylbutyrate, L-leucine, and vitamin D3), addressing the intestinal decline problems of the elderly. Calcium citrate, zinc lactate, and magnesium sulfate, as mineral components, can better synergistically regulate calcium and phosphorus metabolism with vitamin D3, maintaining muscle contraction and nerve conduction, and preventing sarcopenia combined with osteoporosis. Vitamin C can inhibit oxidative stress-induced muscle cell damage while protecting vitamin D3 and amino acids from oxidation, improving product stability. Erythritol, a sugar-free, low-calorie flavoring ingredient, improves taste and increases user compliance. Fumed silica and magnesium stearate, as molding excipients, prevent powder from absorbing moisture, clumping, and separating, ensuring uniform mixing.

[0028] In this invention, the whey protein isolate is preferably 8-15 parts by weight, more preferably 10-14 parts, and even more preferably 13 parts; the soybean oligopeptide is preferably 2-5 parts by weight, more preferably 2.5-4 parts, and even more preferably 3 parts; the fructooligosaccharide is preferably 1-2.5 parts by weight, more preferably 1.5-2.2 parts, and even more preferably 1.8 parts; the inulin is preferably 0.5-1.5 parts by weight, more preferably 0.8-1.2 parts, and even more preferably 1 part; the calcium citrate is preferably 0.3-0.6 parts by weight, more preferably 0.35-0.55 parts, and even more preferably 0.45 parts; and the zinc lactate is preferably 0.005-0.015 parts by weight, more preferably 0.005 parts. The preferred weight percentages are: 8-0.012 parts, more preferably 0.01 parts; the preferred weight percentages of magnesium sulfate are: 0.02-0.05 parts, more preferably 0.025-0.04 parts, and even more preferably 0.035 parts; the preferred weight percentages of vitamin C are: 0.05-0.15 parts, more preferably 0.08-0.12 parts, and even more preferably 0.1 parts; the preferred weight percentages of erythritol are: 3-8 parts, more preferably 4-7 parts, and even more preferably 5 parts; the preferred weight percentages of fumed silica are: 0.1-0.3 parts, more preferably 0.15-0.25 parts, and even more preferably 0.2 parts; and the preferred weight percentages of magnesium stearate are: 0.05-0.2 parts, more preferably 0.08-0.15 parts, and even more preferably 0.1 parts.

[0029] In this invention, the dosage form of the composition is any one of powder, granules, chewable tablets, or oral suspension.

[0030] The present invention also provides a method for preparing the fortified nutritional composition, comprising the following steps:

[0031] (1) Mix fumed silica with pretreated vitamin D3 to obtain mixture A;

[0032] (2) Mix mixture A with calcium β-hydroxy-β-methylbutyrate and L-leucine to obtain mixture B;

[0033] (3) Add whey protein isolate, soybean oligopeptides, fructooligosaccharides, inulin, calcium citrate, zinc lactate, magnesium sulfate, vitamin C and erythritol into mixture B in three equal portions, and then add magnesium stearate and mix well to obtain the final product.

[0034] In this invention, vitamin D3 is pretreated. The preferred pretreatment procedure is to dissolve vitamin D3 in medium-chain triglycerides, then add β-cyclodextrin for inclusion reaction, and freeze-dry.

[0035] In this invention, β-cyclodextrin is added to vitamin D3 dissolved in medium-chain triglycerides to carry out an inclusion reaction. The mass ratio of vitamin D3 to β-cyclodextrin is preferably 1:(250-1000), more preferably 1:(300-800), and even more preferably 1:500. The inclusion reaction is accompanied by stirring. The temperature of the inclusion reaction is preferably 25±1℃. The time of the inclusion reaction (which is also the stirring time) is preferably 50-70 min, more preferably 55-65 min, and even more preferably 60 min.

[0036] In this invention, after the inclusion reaction is completed, freeze-drying is performed. The specific operation of the freeze-drying is preferably as follows: pre-freezing at -(20-25)℃ for 10-12h, and then vacuum drying at a vacuum degree of 10-20Pa and a cold trap temperature of ≤-45℃ for 20-24h to obtain the active and stable vitamin D3 cyclodextrin inclusion complex (i.e., pretreated vitamin D3).

[0037] In this invention, fumed silica is mixed with a vitamin D3 cyclodextrin inclusion complex to obtain mixture A. The mixing time is preferably 3-8 minutes, more preferably 4-6 minutes, and even more preferably 5 minutes.

[0038] In this invention, calcium β-hydroxy-β-methylbutyrate and L-leucine are passed through a sieve, and the undersize material is collected for later use. The mesh size of the sieve is preferably 60-100 mesh, more preferably 70-90 mesh, and even more preferably 80 mesh.

[0039] In this invention, mixture A is mixed with sieved calcium β-hydroxy-β-methylbutyrate and L-leucine at a low speed. The mixing speed is preferably 10-20 r / min, more preferably 12-18 r / min, and even more preferably 15 r / min. The mixing time is preferably 8-12 min, more preferably 9-11 min, and even more preferably 10 min.

[0040] In this invention, preferably, whey protein isolate, soybean oligopeptides, fructooligosaccharides, and inulin are sieved through a screen, and the sieved material is collected for later use. The mesh size of the screen is preferably 40-80 mesh, more preferably 50-70 mesh, and even more preferably 60 mesh.

[0041] In this invention, sieved whey protein isolate, soybean oligopeptides, fructooligosaccharides, and inulin, along with calcium citrate, zinc lactate, magnesium sulfate, vitamin C, and erythritol, are added to mixture B in three equal portions. The mixing time after each addition is preferably 5-10 minutes, more preferably 6-9 minutes, and even more preferably 8 minutes. Then, magnesium stearate is added and mixed thoroughly. The mixing time for this step is preferably 3-8 minutes, more preferably 4-7 minutes, and even more preferably 5 minutes. During each stage of the mixing process, the ambient temperature is controlled at 20-25°C, the ambient humidity at ≤45%, and the operation is carried out in the dark.

[0042] In this invention, the material obtained by the final uniform mixing is aseptically dispensed and sealed to obtain the finished product; it can be further processed such as granulation, drying, tableting, sterilization and filling according to dosage form requirements.

[0043] The application of the fortified nutritional composition described in this invention in the preparation of functional foods that help treat frailty / sarcopenia in the elderly.

[0044] The technical solutions provided by the present invention will be described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0045] Example 1

[0046] A fortified nutritional composition for elderly frail / sarcopenic individuals, with the following components:

[0047] 1.5 parts calcium β-hydroxy-β-methylbutyrate, 1.2 parts L-leucine, 0.000025 parts vitamin D3, 13 parts whey protein isolate, 3 parts soybean oligopeptides, 1.8 parts fructooligosaccharides, 1 part inulin, 0.45 parts calcium citrate, 0.01 parts zinc lactate, 0.035 parts magnesium sulfate, 0.1 parts vitamin C, 5 parts erythritol, 0.2 parts fumed silica, and 0.1 parts magnesium stearate.

[0048] Example 2

[0049] A fortified nutritional composition for elderly frail / sarcopenic individuals, with the following components:

[0050] 1 part calcium β-hydroxy-β-methylbutyrate, 0.8 parts L-leucine, 0.0000125 parts vitamin D3, 15 parts whey protein isolate, 2 parts soybean oligopeptides, 2.5 parts fructooligosaccharides, 1.5 parts inulin, 0.3 parts calcium citrate, 0.005 parts zinc lactate, 0.02 parts magnesium sulfate, 0.05 parts vitamin C, 3 parts erythritol, 0.1 parts fumed silica, and 0.05 parts magnesium stearate.

[0051] Example 3

[0052] A fortified nutritional composition for elderly frail / sarcopenic individuals, with the following components:

[0053] 3 parts calcium β-hydroxy-β-methylbutyrate, 2 parts L-leucine, 0.00005 parts vitamin D3, 8 parts whey protein isolate, 5 parts soybean oligopeptides, 1 part fructooligosaccharides, 0.5 parts inulin, 0.6 parts calcium citrate, 0.015 parts zinc lactate, 0.05 parts magnesium sulfate, 0.15 parts vitamin C, 8 parts erythritol, 0.3 parts fumed silica, and 0.2 parts magnesium stearate.

[0054] Example 4

[0055] The preparation method of the fortified nutritional composition for frail / sarcopenic elderly people described in Example 1 includes the following steps:

[0056] (1) Vitamin D3 was dissolved in medium-chain triglycerides, and then β-cyclodextrin was added at a mass ratio of 1:500 to carry out inclusion reaction. The mixture was stirred at 25±1℃ for 60 min. After that, it was pre-frozen at -22℃ for 10 h, and then vacuum dried at 15 Pa and cold trap temperature ≤-45℃ for 22 h to obtain vitamin D3 cyclodextrin inclusion complex.

[0057] (2) Mix fumed silica with vitamin D3 cyclodextrin inclusion complex for 5 min to obtain mixture A;

[0058] (3) β-hydroxy-β-methylbutyrate calcium and L-leucine are passed through an 80-mesh sieve, and whey protein isolate, soybean oligopeptides, fructooligosaccharides and inulin are passed through a 60-mesh sieve. The sieve residues are collected and set aside.

[0059] (4) Mix mixture A with calcium β-hydroxy-β-methylbutyrate and L-leucine that have been sieved in step (3) at a low speed of 15 r / min for 10 min to obtain mixture B;

[0060] (5) Add the whey protein isolate, soybean oligopeptides, fructooligosaccharides and inulin after sieving in step (3) to mixture B in three equal portions, along with calcium citrate, zinc lactate, magnesium sulfate, vitamin C and erythritol. The mixing time is 8 minutes after each addition. Finally, add magnesium stearate and mix for 5 minutes. The temperature is 20-25℃, the humidity is ≤45%, and the mixture is kept away from light throughout the process.

[0061] (6) The material obtained by the final uniform mixing in step (5) is aseptically dispensed and sealed to obtain the finished product.

[0062] Example 5

[0063] The preparation method of the fortified nutritional composition for frail / sarcopenic elderly people described in Example 1 includes the following steps:

[0064] (1) Vitamin D3 was dissolved in medium-chain triglycerides, and then β-cyclodextrin was added at a mass ratio of 1:250 to carry out the inclusion reaction. The mixture was stirred at 25±1℃ for 50 min. After that, it was pre-frozen at -20℃ for 12 h, and then vacuum dried at 20 Pa and cold trap temperature ≤-45℃ for 20 h to obtain vitamin D3 cyclodextrin inclusion complex.

[0065] (2) Mix fumed silica with vitamin D3 cyclodextrin inclusion complex for 3 min to obtain mixture A;

[0066] (3) β-hydroxy-β-methylbutyrate calcium and L-leucine are passed through a 60-mesh sieve, and whey protein isolate, soybean oligopeptides, fructooligosaccharides and inulin are passed through a 40-mesh sieve. The sieve residues are collected and set aside.

[0067] (4) Mix mixture A with calcium β-hydroxy-β-methylbutyrate and L-leucine that have been sieved in step (3) at a low speed of 10 r / min for 12 min to obtain mixture B;

[0068] (5) Add the whey protein isolate, soybean oligopeptides, fructooligosaccharides and inulin after sieving in step (3) to mixture B in equal amounts in three separate additions, along with calcium citrate, zinc lactate, magnesium sulfate, vitamin C and erythritol. The mixing time is 5 minutes after each addition. Finally, add magnesium stearate and mix for 8 minutes. The temperature is 20-25℃, the humidity is ≤45%, and the mixture is kept away from light throughout the process.

[0069] (6) The material obtained by the final uniform mixing in step (5) is aseptically dispensed and sealed to obtain the finished product.

[0070] Example 6

[0071] The preparation method of the fortified nutritional composition for frail / sarcopenic elderly people described in Example 1 includes the following steps:

[0072] (1) Dissolve vitamin D3 in medium-chain triglycerides, and then add β-cyclodextrin at a mass ratio of 1:1000 to carry out inclusion reaction. Stir at 25±1℃ for 70 min; then pre-freeze at -25℃ for 10 h, and then vacuum dry at 10 Pa and cold trap temperature ≤-45℃ for 24 h to obtain vitamin D3 cyclodextrin inclusion complex.

[0073] (2) Mix fumed silica with vitamin D3 cyclodextrin inclusion complex for 8 min to obtain mixture A;

[0074] (3) β-hydroxy-β-methylbutyrate calcium and L-leucine are passed through a 100-mesh sieve, and whey protein isolate, soybean oligopeptides, fructooligosaccharides and inulin are passed through an 80-mesh sieve. The sieve residues are collected and set aside.

[0075] (4) Mix mixture A with calcium β-hydroxy-β-methylbutyrate and L-leucine that have been sieved in step (3) at a low speed of 20 r / min for 18 min to obtain mixture B;

[0076] (5) Add the whey protein isolate, soybean oligopeptides, fructooligosaccharides and inulin after sieving in step (3) to mixture B in equal amounts in three separate additions, along with calcium citrate, zinc lactate, magnesium sulfate, vitamin C and erythritol. The mixing time is 10 min after each addition. Finally, add magnesium stearate and mix for 3 min. The temperature should be 20-25℃, the humidity ≤45%, and the mixture should be kept away from light throughout the process.

[0077] (6) The material obtained by the final uniform mixing in step (5) is aseptically dispensed and sealed to obtain the finished product.

[0078] Example 7

[0079] The preparation method of the fortified nutritional composition for frail / sarcopenic elderly people described in Example 2 includes the following steps:

[0080] (1) Vitamin D3 was dissolved in medium-chain triglycerides, and then β-cyclodextrin was added at a mass ratio of 1:500 to carry out inclusion reaction. The mixture was stirred at 25±1℃ for 60 min. After that, it was pre-frozen at -22℃ for 10 h, and then vacuum dried at 15 Pa and cold trap temperature ≤-45℃ for 22 h to obtain vitamin D3 cyclodextrin inclusion complex.

[0081] (2) Mix fumed silica with vitamin D3 cyclodextrin inclusion complex for 5 min to obtain mixture A;

[0082] (3) β-hydroxy-β-methylbutyrate calcium and L-leucine are passed through an 80-mesh sieve, and whey protein isolate, soybean oligopeptides, fructooligosaccharides and inulin are passed through a 60-mesh sieve. The sieve residues are collected and set aside.

[0083] (4) Mix mixture A with calcium β-hydroxy-β-methylbutyrate and L-leucine that have been sieved in step (3) at a low speed of 15 r / min for 10 min to obtain mixture B;

[0084] (5) Add the whey protein isolate, soybean oligopeptides, fructooligosaccharides and inulin after sieving in step (3) to mixture B in three equal portions, along with calcium citrate, zinc lactate, magnesium sulfate, vitamin C and erythritol. The mixing time is 8 minutes after each addition. Finally, add magnesium stearate and mix for 5 minutes. The temperature is 20-25℃, the humidity is ≤45%, and the mixture is kept away from light throughout the process.

[0085] (6) The material obtained by the final uniform mixing in step (5) is aseptically dispensed and sealed to obtain the finished product.

[0086] Example 8

[0087] The preparation method of the fortified nutritional composition for frail / sarcopenic elderly people described in Example 3 includes the following steps:

[0088] (1) Vitamin D3 was dissolved in medium-chain triglycerides, and then β-cyclodextrin was added at a mass ratio of 1:500 to carry out inclusion reaction. The mixture was stirred at 25±1℃ for 60 min. After that, it was pre-frozen at -22℃ for 10 h, and then vacuum dried at 15 Pa and cold trap temperature ≤-45℃ for 22 h to obtain vitamin D3 cyclodextrin inclusion complex.

[0089] (2) Mix fumed silica with vitamin D3 cyclodextrin inclusion complex for 5 min to obtain mixture A;

[0090] (3) β-hydroxy-β-methylbutyrate calcium and L-leucine are passed through an 80-mesh sieve, and whey protein isolate, soybean oligopeptides, fructooligosaccharides and inulin are passed through a 60-mesh sieve. The sieve residues are collected and set aside.

[0091] (4) Mix mixture A with calcium β-hydroxy-β-methylbutyrate and L-leucine that have been sieved in step (3) at a low speed of 15 r / min for 10 min to obtain mixture B;

[0092] (5) Add the whey protein isolate, soybean oligopeptides, fructooligosaccharides and inulin after sieving in step (3) to mixture B in three equal portions, along with calcium citrate, zinc lactate, magnesium sulfate, vitamin C and erythritol. The mixing time is 8 minutes after each addition. Finally, add magnesium stearate and mix for 5 minutes. The temperature is 20-25℃, the humidity is ≤45%, and the mixture is kept away from light throughout the process.

[0093] (6) The material obtained by the final uniform mixing in step (5) is aseptically dispensed and sealed to obtain the finished product.

[0094] Comparative Example 1

[0095] Similar to Example 4, only "β-hydroxy-β-methylbutyrate calcium and L-leucine" were removed.

[0096] Comparative Example 2

[0097] Similar to Example 4, only "Vitamin D3" was removed.

[0098] Comparative Example 3

[0099] Similar to Example 4, except that “1.5 parts of calcium β-hydroxy-β-methylbutyrate, 1.2 parts of L-leucine, and 0.000025 parts of vitamin D3” is replaced with “0.5 parts of calcium β-hydroxy-β-methylbutyrate, 3 parts of L-leucine, and 0.00001 parts of vitamin D3”.

[0100] Comparative Example 4

[0101] Similar to Example 4, only the "fumed silica" was removed.

[0102] Comparative Example 5

[0103] Similar to Example 4, only the vitamin D3 pretreatment process was removed: "Dissolve vitamin D3 in medium-chain triglycerides, then add β-cyclodextrin at a mass ratio of 1:500 for inclusion reaction, stir at 25±1℃ for 60 min; then pre-freeze at -22℃ for 10 h, and then vacuum dry at 15 Pa and cold trap temperature ≤-45℃ for 22 h to obtain vitamin D3 cyclodextrin inclusion complex".

[0104] Comparative Example 6

[0105] Similar to Example 4, except that “the whey protein isolate, soybean oligopeptides, fructooligosaccharides and inulin after sieving in step (3), along with calcium citrate, zinc lactate, magnesium sulfate, vitamin C and erythritol, are added to mixture B in equal amounts in three separate additions, with a mixing time of 8 minutes after each addition” is replaced with “the whey protein isolate, soybean oligopeptides, fructooligosaccharides and inulin after sieving in step (3), along with calcium citrate, zinc lactate, magnesium sulfate, vitamin C and erythritol, are added to mixture B and mixed for 24 minutes”.

[0106] Experimental Example 1

[0107] (a) Safety test

[0108] 1. Acute toxicity test

[0109] Eighty naturally aged (22 months old, 34±2g) C57BL / 6J mice (simulating elderly sarcopenia patients, purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd.) were selected and randomly divided into 8 groups of 10 mice each, half male and half female, including Example 4, Comparative Example 1, Comparative Example 2, Comparative Example 3, Comparative Example 4, Comparative Example 5, Comparative Example 6 and blank group.

[0110] Take 22g of each of the products prepared by the corresponding examples and comparative examples, dissolve them in 88mL of physiological saline, and administer them by gavage at a volume of 2mL / 10g body weight; the blank group is given an equal volume of physiological saline, and the mice are observed for 7 consecutive days. The survival status, food and water intake, weight changes and poisoning deaths of the mice are recorded.

[0111] The results showed that all mice maintained good mental condition, normal diet and water intake, and free movement throughout the experimental period, without any abnormal symptoms of poisoning such as agitation, lethargy, diarrhea, or vomiting, and no mice died. Mouse weight gain was stable with no significant differences between groups. Dissection of major organs such as the heart, liver, spleen, lungs, and kidneys after the experiment revealed no pathological changes such as congestion, edema, or necrosis. These results indicate that the fortified nutritional composition prepared in this invention has no acute toxic reactions when administered orally, and is safe and reliable for short-term consumption.

[0112] 2. Long-term toxicity testing

[0113] To verify the long-term biosafety of the composition of this invention, a 12-week long-term toxicity test was conducted. Eighty naturally aged (22 months old) C57BL / 6J mice were randomly divided into a high-dose group, a medium-dose group, a low-dose group, and a control group, with 20 mice in each group (half male and half female). The high, medium, and low doses were 8 times, 4 times, and 2 times the amount consumed by patients, respectively, and were mixed with warm water at a 1:1 ratio to form a paste. The mice were administered the paste by gavage for 12 consecutive weeks. During the test, the mice's mental state and body weight were observed. After the test, liver and kidney function and organ indices were measured.

[0114] The results showed that during the 12-week long-term intervention, the mice in each dosage group had normal mental state, diet, and activity, with no deaths or poisoning. There were no statistically significant differences in liver and kidney function indicators and liver and kidney organ indices between the groups and the control group. This indicates that the fortified nutritional composition prepared in this invention has no liver or kidney toxicity or cumulative toxicity at the stated dosage and multiples thereof, demonstrating extremely high biosafety and suitability for long-term continuous use by the elderly.

[0115] (ii) Impregnation and stability test

[0116] 1. Impregnation and adaptability test

[0117] Using 45℃ warm water (a commonly used brewing temperature for the elderly, avoiding the problems of heat-sensitive component inactivation at high temperatures and poor dissolution at low temperatures), the solid-liquid ratio was 1:10 (22g powder / 220mL warm water), and the mixture was stirred clockwise at a uniform speed for 30s. The complete dissolution time, bottom sedimentation amount, and stratification of each powder in Example 4 and Comparative Examples 1-6 were measured respectively. The dissolution stability coefficient was calculated to comprehensively evaluate the uniformity of preparation and rapid solubility.

[0118] Settling rate (%) = (Amount of sediment at the bottom after reconstitution / Total mass of powder) × 100%

[0119] Table 1. Results of rehydration properties in different treatment groups

[0120]

[0121] As can be seen from Table 1, the powder composition of the present invention has excellent rapid solubility. It can be quickly and completely dissolved under warm water conditions. The solution is clear and uniform, without obvious clumping or precipitation. The solubility stability coefficient is close to 99%, which is significantly better than the comparative example group.

[0122] 2. Stability test

[0123] The powders prepared in Example 4 and Comparative Examples 1-6 were sealed and placed in a constant temperature and humidity accelerated testing chamber at 40°C and 75% relative humidity for 90 days. Samples were taken at 0, 30, 60, and 90 days for testing. The test indicators included powder moisture content, powder color, and retention rate of active ingredient (vitamin D3) to evaluate the powder stability and activity retention capacity during product storage.

[0124] The determination of powder moisture content refers to GB 5009.3-2016 "National Food Safety Standard - Determination of Moisture in Food"; the determination of vitamin D3 refers to GB 5009.296-2023 "National Food Safety Standard - Determination of Vitamin D in Food".

[0125] Active ingredient retention rate (%) = (Active ingredient content of the sample after 90 days of accelerated storage / Active ingredient content of the initial sample at 0 days) × 100%

[0126] Table 2. Stability of different treatment groups

[0127]

[0128] Note: "-" indicates that vitamin D3 was not added to this treatment group and there is no corresponding test data.

[0129] The results show that the powder composition of Example 4 of this invention has extremely low moisture absorption and is not prone to moisture absorption and clumping during long-term storage; the retention rate of the core active component, vitamin D3, is at a high level, and the stability of the active ingredients is excellent. Simultaneously, the powder's reconstitution performance shows no significant decline after storage, the sedimentation rate is extremely low, and the microbiological indicators fully comply with food safety standards, with no mold or spoilage. This also indicates that this invention, through vitamin D3 cyclodextrin inclusion technology, modification of the powder with inert excipients, and a low-humidity, light-protected preparation process, significantly improves the stability of heat-sensitive components and the overall uniformity of the powder, resulting in more stable quality over the shelf life.

[0130] Experimental Example 2

[0131] All human clinical studies involved in this trial have been reviewed and approved by the relevant clinical trial institution's ethics committee in advance. The entire trial process strictly followed the ethical guidelines of the Declaration of Helsinki and relevant clinical trial quality management standards in my country. All subjects included in this study or their legal representatives participated voluntarily after fully understanding the research objectives, intervention methods, expected benefits, and potential risks. During the trial, strict confidentiality was maintained over the personal privacy and clinical data of all subjects.

[0132] Two hundred and forty elderly patients with sarcopenia were recruited and randomly divided into eight groups: a control group, Example 1 group, and Comparative Examples 1-6 groups, with 30 patients in each group. The mean age of each group was 65 ± 2 years, and the mean body mass index (BMI) was 22 ± 1 kg / m². 3 .

[0133] Inclusion criteria: (1) Patients were over 60 years of age; (2) Patients met the diagnostic criteria for sarcopenia in the "Guidelines for Clinical Rehabilitation Treatment of Sarcopenia in Chinese Elderly"; (3) Patients had a muscle strength grade of 3 or above; (4) Patients had complete clinical data; (5) Patients were informed about the treatment plan developed in this study and were able to adhere to it until the treatment endpoint. All patients who met the above criteria were included in this study.

[0134] Exclusion criteria: (1) Comorbid severe autoimmune disease or hematologic disease; (2) Comorbid liver failure or severe coagulation dysfunction; (3) Comorbid benign or malignant tumor of any type; (4) Comorbid acute or chronic infectious disease of any type.

[0135] Each group of patients received a uniform basic dietary intervention. Patients in Example 4 and Comparative Examples 1-6 were given the corresponding prepared composition product, 22g once daily for 12 weeks. The control group received no treatment. Core efficacy indicators, including limb skeletal muscle mass (ASM), 6m walking time, and hand grip strength (HGS) of the dominant hand measured using a hand gripper, were assessed at weeks 0 and 12 of the intervention. The average value was calculated after three measurements.

[0136] Table 3. Core efficacy indicators of patients in different treatment groups

[0137]

[0138] The results showed that the composition prepared by Example 1 with the optimal ratio of the present invention could significantly improve skeletal muscle mass, limb muscle strength and physical mobility in elderly subjects with sarcopenia, effectively improve the degree of frailty in the elderly, and the improvement of various core efficacy indicators was significantly better than that of the comparative groups.

[0139] In summary, the technical solution of this invention uses calcium β-hydroxy-β-methylbutyrate, L-leucine, and vitamin D3 in a limited ratio as core active components, and combines them with small molecule active peptides, prebiotics, minerals, and food-grade excipients to construct a synergistic nutritional system, forming a synergistic mechanism of "promoting synthesis, inhibiting decomposition, enhancing function, and improving absorption", which is precisely adapted to the metabolic characteristics of frailty / sarcopenia in the elderly and improves muscle mass, muscle strength, and exercise capacity.

[0140] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A fortified nutritional composition for elderly frail / sarcopenic individuals, characterized in that, It includes the following core active ingredients in parts by weight: 1-3 parts of calcium β-hydroxy-β-methylbutyrate, 0.8-2 parts of L-leucine, and 0.0000125-0.00005 parts of vitamin D3.

2. The fortified nutritional composition according to claim 1, characterized in that, It also includes food-grade excipients, which, by weight, include: 8-15 parts whey protein isolate, 2-5 parts soybean oligopeptides, 1-2.5 parts fructooligosaccharides, 0.5-1.5 parts inulin, 0.3-0.6 parts calcium citrate, 0.005-0.015 parts zinc lactate, 0.02-0.05 parts magnesium sulfate, 0.05-0.15 parts vitamin C, 3-8 parts erythritol, 0.1-0.3 parts fumed silica, and 0.05-0.2 parts magnesium stearate.

3. The fortified nutritional composition according to claim 1, characterized in that, The dosage form of the composition is any one of powder, granules, chewable tablets, or oral suspension.

4. A method for preparing the fortified nutritional composition according to any one of claims 1-3, characterized in that, Includes the following steps: (1) Mix fumed silica with pretreated vitamin D3 to obtain mixture A; (2) Mix mixture A with calcium β-hydroxy-β-methylbutyrate and L-leucine to obtain mixture B; (3) Add whey protein isolate, soybean oligopeptides, fructooligosaccharides, inulin, calcium citrate, zinc lactate, magnesium sulfate, vitamin C and erythritol into mixture B in three equal portions, and then add magnesium stearate and mix well to obtain the final product.

5. The preparation method according to claim 4, characterized in that, The pretreatment operation in step (1) is as follows: dissolve vitamin D3 in medium-chain triglycerides, then add β-cyclodextrin for inclusion reaction, and freeze dry.

6. The preparation method according to claim 5, characterized in that, The mass ratio of vitamin D3 to β-cyclodextrin is 1:(250-1000).

7. The preparation method according to claim 5, characterized in that, The inclusion reaction is carried out at a temperature of 25±1℃ and for a time of 50-70 min.

8. The preparation method according to claim 4, characterized in that, In step (3), during the process of adding equal amounts three times, the mixing time after each addition is 5-10 minutes; The mixing time for the magnesium stearate is 3-8 minutes.

9. The use of the fortified nutritional composition according to any one of claims 1-3, or the fortified nutritional composition prepared by the preparation method according to any one of claims 4-8, in the preparation of functional foods that help regulate senile frailty / sarcopenia.